OBJECTIVE: In the Netherlands over 11 200 patients are yearly diagnosed with colorectal cancer (CRC), of who about 4 700 are expected to die of the disease ultimately. Investigating long-term trends is useful for clinicians and policy makers to evaluate the impact of changes in practice and will help predict future developments. PATIENTS: The 26 826 cases of primary CRC (C18.0-C20.9) diagnosed between 1975 and 2007 in the Dutch population-based Eindhoven Cancer Registry area were included. We analysed trends in incidence, prevalence, stage distribution, treatment, survival, and mortality. RESULTS: The age-standardised incidence of colon carcinoma kept increasing, most markedly in males (up to 39 patients per 100 000 inhabitants) and for tumours of the colon ascendens (subsite-specific incidence doubled). The incidence of rectal carcinoma remained stable. The share of patients aged 80 or older rose from 12 to 19% (p<0.0001). The proportion of patients diagnosed with distant metastases increased up to 25% for colon carcinoma (p<0.0001). Resection rates of the primary tumour remained high except for patients with metastasised disease, showing a decrease since 2000. Recently, the use of adjuvant chemotherapy seemed to level off among patients with stage III colon carcinoma, but the use of neo-adjuvant chemoradiation clearly increased among patients with stage II/III rectal cancer (p<0.0001). Five-year relative survival of colon cancer improved from 51% in 1975-1984 to 58% in 2000-2004, for rectal cancer it improved from 44 to 59%. Two-year relative survival of colon cancer in 2005-2006 was 69%, and 77% for rectal cancer. CONCLUSIONS: The changes in management of rectal cancer led to a superior increase in survival of these patients compared to patients with colon cancer, even surpassing the latter.
OBJECTIVE: In the Netherlands over 11 200 patients are yearly diagnosed with colorectal cancer (CRC), of who about 4 700 are expected to die of the disease ultimately. Investigating long-term trends is useful for clinicians and policy makers to evaluate the impact of changes in practice and will help predict future developments. PATIENTS: The 26 826 cases of primary CRC (C18.0-C20.9) diagnosed between 1975 and 2007 in the Dutch population-based Eindhoven Cancer Registry area were included. We analysed trends in incidence, prevalence, stage distribution, treatment, survival, and mortality. RESULTS: The age-standardised incidence of colon carcinoma kept increasing, most markedly in males (up to 39 patients per 100 000 inhabitants) and for tumours of the colon ascendens (subsite-specific incidence doubled). The incidence of rectal carcinoma remained stable. The share of patients aged 80 or older rose from 12 to 19% (p<0.0001). The proportion of patients diagnosed with distant metastases increased up to 25% for colon carcinoma (p<0.0001). Resection rates of the primary tumour remained high except for patients with metastasised disease, showing a decrease since 2000. Recently, the use of adjuvant chemotherapy seemed to level off among patients with stage III colon carcinoma, but the use of neo-adjuvant chemoradiation clearly increased among patients with stage II/III rectal cancer (p<0.0001). Five-year relative survival of colon cancer improved from 51% in 1975-1984 to 58% in 2000-2004, for rectal cancer it improved from 44 to 59%. Two-year relative survival of colon cancer in 2005-2006 was 69%, and 77% for rectal cancer. CONCLUSIONS: The changes in management of rectal cancer led to a superior increase in survival of these patients compared to patients with colon cancer, even surpassing the latter.
Authors: Arantza Fariña Sarasqueta; Eliane C M Zeestraten; Tom van Wezel; Gesina van Lijnschoten; Ronald van Eijk; Jan Willem T Dekker; Peter J K Kuppen; Ines J Goossens-Beumer; Valery E P P Lemmens; Cornelis J H van de Velde; Harm J T Rutten; Hans Morreau; A J C van den Brule Journal: Cell Oncol (Dordr) Date: 2011-08-10 Impact factor: 6.730
Authors: Iris Lansdorp-Vogelaar; S Lucas Goede; Linda J W Bosch; Veerle Melotte; Beatriz Carvalho; Manon van Engeland; Gerrit A Meijer; Harry J de Koning; Marjolein van Ballegooijen Journal: Clin Gastroenterol Hepatol Date: 2017-07-18 Impact factor: 11.382
Authors: Olga Husson; Melissa S Y Thong; Floortje Mols; Tineke J Smilde; Geert-Jan Creemers; Lonneke V van de Poll-Franse Journal: J Palliat Med Date: 2013-03 Impact factor: 2.947
Authors: Minna Räsänen; Monika Carpelan-Holmström; Harri Mustonen; Laura Renkonen-Sinisalo; Anna Lepistö Journal: Int J Colorectal Dis Date: 2015-03-22 Impact factor: 2.571
Authors: Melissa S Y Thong; Floortje Mols; Xin S Wang; Valery E P P Lemmens; Tineke J Smilde; Lonneke V van de Poll-Franse Journal: Eur J Cancer Date: 2013-03-01 Impact factor: 9.162